For discussion: live attenuated vaccines for group B meningococcus

Vaccine. 1999 Jan;17(2):114-7. doi: 10.1016/s0264-410x(98)00163-7.

Abstract

Current attempts at preventing infections caused by group B Neisseria meningitidis are largely directed on generating immune responses to outer membrane proteins or the lipopolysaccharide of this organism. We suggest an alternative approach: the use of a live, attenuated strain of Neisseria meningitidis which could be delivered mucosally to elicit both local and systemic immune responses.

Publication types

  • Review

MeSH terms

  • Bacterial Vaccines / adverse effects
  • Bacterial Vaccines / isolation & purification*
  • Bacterial Vaccines / pharmacology
  • Humans
  • Meningococcal Infections / immunology
  • Meningococcal Infections / prevention & control
  • Meningococcal Vaccines
  • Neisseria meningitidis / classification*
  • Neisseria meningitidis / immunology*
  • Neisseria meningitidis / pathogenicity
  • Safety
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / isolation & purification
  • Vaccines, Attenuated / pharmacology

Substances

  • Bacterial Vaccines
  • Meningococcal Vaccines
  • Vaccines, Attenuated